| Literature DB >> 27044531 |
Deborah J Levine1, Allan R Glanville2, Christina Aboyoun3, John Belperio4, Christian Benden5, Gerald J Berry6, Ramsey Hachem7, Don Hayes8, Desley Neil9, Nancy L Reinsmoen10, Laurie D Snyder11, Stuart Sweet7, Dolly Tyan6, Geert Verleden12, Glen Westall13, Roger D Yusen7, Martin Zamora14, Adriana Zeevi15.
Abstract
Antibody-mediated rejection (AMR) is a recognized cause of allograft dysfunction in lung transplant recipients. Unlike AMR in other solid-organ transplant recipients, there are no standardized diagnostic criteria or an agreed-upon definition. Hence, a working group was created by the International Society for Heart and Lung Transplantation with the aim of determining criteria for pulmonary AMR and establishing a definition. Diagnostic criteria and a working consensus definition were established. Key diagnostic criteria include the presence of antibodies directed toward donor human leukocyte antigens and characteristic lung histology with or without evidence of complement 4d within the graft. Exclusion of other causes of allograft dysfunction increases confidence in the diagnosis but is not essential. Pulmonary AMR may be clinical (allograft dysfunction which can be asymptomatic) or sub-clinical (normal allograft function). This consensus definition will have clinical, therapeutic and research implications.Entities:
Keywords: HLA antibodies; allograft dysfunction; lung transplantation; rejection
Mesh：
Substances：
Year: 2016 PMID： 27044531 DOI： 10.1016/j.healun.2016.01.1223
Source DB: PubMed Journal: J Heart Lung Transplant ISSN： 1053-2498 Impact factor: 10.247